Search

Ileana Popa

Examiner (ID: 13683, Phone: (571)272-5546 , Office: P/1633 )

Most Active Art Unit
1633
Art Unit(s)
1633
Total Applications
1101
Issued Applications
184
Pending Applications
130
Abandoned Applications
810

Applications

Application numberTitle of the applicationFiling DateStatus
Array ( [id] => 15361019 [patent_doc_number] => 20200016274 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-01-16 [patent_title] => MESSENGER RNA VACCINES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/425693 [patent_app_country] => US [patent_app_date] => 2019-05-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19134 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16425693 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/425693
MESSENGER RNA VACCINES AND USES THEREOF May 28, 2019 Abandoned
Array ( [id] => 17258873 [patent_doc_number] => 20210371858 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-02 [patent_title] => METHODS OF SUPPRESSING PATHOGENIC MUTATIONS USING PROGRAMMABLE BASE EDITOR SYSTEMS [patent_app_type] => utility [patent_app_number] => 17/054393 [patent_app_country] => US [patent_app_date] => 2019-05-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 73379 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17054393 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/054393
METHODS OF SUPPRESSING PATHOGENIC MUTATIONS USING PROGRAMMABLE BASE EDITOR SYSTEMS May 10, 2019 Pending
Array ( [id] => 14994263 [patent_doc_number] => 20190316089 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-17 [patent_title] => SYNTHETIC MEMBRANE-RECEIVER COMPLEXES [patent_app_type] => utility [patent_app_number] => 16/409576 [patent_app_country] => US [patent_app_date] => 2019-05-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 131020 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 44 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16409576 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/409576
Erythroid cells comprising phenylalanine ammonia lyase May 9, 2019 Issued
Array ( [id] => 14778559 [patent_doc_number] => 20190264177 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-29 [patent_title] => SYNTHETIC MEMBRANE-RECEIVER COMPLEXES [patent_app_type] => utility [patent_app_number] => 16/409573 [patent_app_country] => US [patent_app_date] => 2019-05-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 131043 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 44 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16409573 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/409573
SYNTHETIC MEMBRANE-RECEIVER COMPLEXES May 9, 2019 Abandoned
Array ( [id] => 19060399 [patent_doc_number] => 11939609 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-03-26 [patent_title] => Rewiring aberrant cancer signaling to a therapeutic effector response with a synthetic two-component system [patent_app_type] => utility [patent_app_number] => 16/400976 [patent_app_country] => US [patent_app_date] => 2019-05-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 86 [patent_figures_cnt] => 86 [patent_no_of_words] => 32216 [patent_no_of_claims] => 36 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 48 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16400976 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/400976
Rewiring aberrant cancer signaling to a therapeutic effector response with a synthetic two-component system Apr 30, 2019 Issued
Array ( [id] => 20466778 [patent_doc_number] => 12522811 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-01-13 [patent_title] => Enhanced BCL11A RNP / CRISPR delivery and editing using a 3XNLS-CAS9 [patent_app_type] => utility [patent_app_number] => 17/051583 [patent_app_country] => US [patent_app_date] => 2019-05-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 61 [patent_figures_cnt] => 121 [patent_no_of_words] => 20738 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 143 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17051583 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/051583
Enhanced BCL11A RNP / CRISPR delivery and editing using a 3XNLS-CAS9 Apr 30, 2019 Issued
Array ( [id] => 19977382 [patent_doc_number] => 12344845 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-07-01 [patent_title] => Highly knotted molecular topologies from single-stranded nucleic acids [patent_app_type] => utility [patent_app_number] => 17/050918 [patent_app_country] => US [patent_app_date] => 2019-04-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 34 [patent_figures_cnt] => 81 [patent_no_of_words] => 22098 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 90 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17050918 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/050918
Highly knotted molecular topologies from single-stranded nucleic acids Apr 24, 2019 Issued
Array ( [id] => 14990669 [patent_doc_number] => 20190314292 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-17 [patent_title] => COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS [patent_app_type] => utility [patent_app_number] => 16/382423 [patent_app_country] => US [patent_app_date] => 2019-04-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 110568 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 12 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16382423 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/382423
Compounds and compositions for intracellular delivery of therapeutic agents Apr 11, 2019 Issued
Array ( [id] => 14960453 [patent_doc_number] => 20190307704 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-10 [patent_title] => METHOD FOR ENHANCED DELIVERY OF GENE BASED THERAPY AND VACCINATION USING ELECTROPORATION [patent_app_type] => utility [patent_app_number] => 16/372710 [patent_app_country] => US [patent_app_date] => 2019-04-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4418 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 41 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16372710 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/372710
METHOD FOR ENHANCED DELIVERY OF GENE BASED THERAPY AND VACCINATION USING ELECTROPORATION Apr 1, 2019 Abandoned
Array ( [id] => 14864755 [patent_doc_number] => 20190282619 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-09-19 [patent_title] => BUOYANCY-ACTIVATED CELL SORTING (BACS)-COMPATIBLE ACTIVATION/TRANSDUCTION SYSTEMS AND METHODS [patent_app_type] => utility [patent_app_number] => 16/353071 [patent_app_country] => US [patent_app_date] => 2019-03-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16763 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 94 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16353071 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/353071
Buoyancy-activated cell sorting (BACS)-compatible activation/transduction systems and methods Mar 13, 2019 Issued
Array ( [id] => 20106996 [patent_doc_number] => 12357694 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-07-15 [patent_title] => Methods and compositions for use of tumor self-antigens in adoptive immunotherapy [patent_app_type] => utility [patent_app_number] => 16/979138 [patent_app_country] => US [patent_app_date] => 2019-03-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 8 [patent_no_of_words] => 29016 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 29 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16979138 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/979138
Methods and compositions for use of tumor self-antigens in adoptive immunotherapy Mar 11, 2019 Issued
Array ( [id] => 16671305 [patent_doc_number] => 20210060068 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-04 [patent_title] => BIOLOGICALLY RELEVANT ORTHOGONAL CYTOKINE/RECEPTOR PAIRS [patent_app_type] => utility [patent_app_number] => 16/977385 [patent_app_country] => US [patent_app_date] => 2019-03-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23129 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 60 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16977385 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/977385
BIOLOGICALLY RELEVANT ORTHOGONAL CYTOKINE/RECEPTOR PAIRS Mar 7, 2019 Abandoned
Array ( [id] => 16009359 [patent_doc_number] => 20200179522 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-11 [patent_title] => NANOSTRUCTURES FOR PENETRATING DEEP INTO CANCER TISSUES [patent_app_type] => utility [patent_app_number] => 16/295567 [patent_app_country] => US [patent_app_date] => 2019-03-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7738 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16295567 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/295567
NANOSTRUCTURES FOR PENETRATING DEEP INTO CANCER TISSUES Mar 6, 2019 Abandoned
Array ( [id] => 14498071 [patent_doc_number] => 20190192690 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-06-27 [patent_title] => LIVER SPECIFIC DELIVERY OF MESSENGER RNA [patent_app_type] => utility [patent_app_number] => 16/286423 [patent_app_country] => US [patent_app_date] => 2019-02-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17628 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16286423 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/286423
LIVER SPECIFIC DELIVERY OF MESSENGER RNA Feb 25, 2019 Abandoned
Array ( [id] => 18544231 [patent_doc_number] => 11717563 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-08-08 [patent_title] => Compositions comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance [patent_app_type] => utility [patent_app_number] => 16/283486 [patent_app_country] => US [patent_app_date] => 2019-02-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 13 [patent_no_of_words] => 24238 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16283486 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/283486
Compositions comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance Feb 21, 2019 Issued
Array ( [id] => 14743829 [patent_doc_number] => 20190255088 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-22 [patent_title] => BIOCOMPATIBLE ORGANO-INORGANIC NANOCOMPOSITES [patent_app_type] => utility [patent_app_number] => 16/277475 [patent_app_country] => US [patent_app_date] => 2019-02-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8195 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 57 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16277475 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/277475
BIOCOMPATIBLE ORGANO-INORGANIC NANOCOMPOSITES Feb 14, 2019 Abandoned
Array ( [id] => 14342257 [patent_doc_number] => 20190153101 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-05-23 [patent_title] => Methods of Treating Sickle Cell Disease [patent_app_type] => utility [patent_app_number] => 16/258134 [patent_app_country] => US [patent_app_date] => 2019-01-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10722 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 41 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16258134 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/258134
Methods of Treating Sickle Cell Disease Jan 24, 2019 Abandoned
Array ( [id] => 17393530 [patent_doc_number] => 11242533 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-02-08 [patent_title] => RNA-nanostructured double robots and methods of use thereof [patent_app_type] => utility [patent_app_number] => 16/954458 [patent_app_country] => US [patent_app_date] => 2019-01-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 46 [patent_no_of_words] => 35745 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 102 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16954458 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/954458
RNA-nanostructured double robots and methods of use thereof Jan 9, 2019 Issued
Array ( [id] => 14960451 [patent_doc_number] => 20190307703 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-10 [patent_title] => MULTI-FUNCTIONAL NANOPARTICLES FOR VACCINATION [patent_app_type] => utility [patent_app_number] => 16/230148 [patent_app_country] => US [patent_app_date] => 2018-12-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5847 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 22 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16230148 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/230148
MULTI-FUNCTIONAL NANOPARTICLES FOR VACCINATION Dec 20, 2018 Abandoned
Array ( [id] => 14213883 [patent_doc_number] => 20190119326 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-04-25 [patent_title] => CYCLIN A1-TARGETED T-CELL IMMUNOTHERAPY FOR CANCER [patent_app_type] => utility [patent_app_number] => 16/228379 [patent_app_country] => US [patent_app_date] => 2018-12-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21902 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 99 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16228379 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/228379
CYCLIN A1-TARGETED T-CELL IMMUNOTHERAPY FOR CANCER Dec 19, 2018 Abandoned
Menu